Cargando…
Comparison of T790M Acquisition Between Patients Treated with Afatinib and Gefitinib as First-Line Therapy: Retrospective Propensity Score Matching Analysis
Afatinib, a second-generation, irreversible pan-HER inhibitor, shows better suppression of T790M-positive lung cancer cells than gefitinib in preclinical studies. However, whether the effect of afatinib on T790M acquisition differs from that of gefitinib when used clinically as first-line therapy re...
Autores principales: | Yoon, Byung Woo, Kim, Jae Hoon, Lee, Seung Hyeon, Choi, Chang-Min, Rho, Jin Kyung, Yoon, Shinkyo, Lee, Dae Ho, Kim, Sang-We, Jang, Tae-Won, Lee, Jae Cheol |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484288/ https://www.ncbi.nlm.nih.gov/pubmed/31030101 http://dx.doi.org/10.1016/j.tranon.2019.04.004 |
Ejemplares similares
-
Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
por: Choi, Hayoung, et al.
Publicado: (2021) -
Optimal Definition of Oligometastasis Showing Survival Benefits of Local Therapies during Tyrosine Kinase Inhibitor Treatment
por: Jang, Yoon Jung, et al.
Publicado: (2023) -
Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung
por: Jang, Yoon Jung, et al.
Publicado: (2021) -
Impact of gender on response to immune checkpoint inhibitors in patients with non-small cell lung cancer undergoing second- or later-line treatment
por: Choi, Myeong Geun, et al.
Publicado: (2022) -
Real‐world utility of next‐generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma
por: Kim, Jwa Hoon, et al.
Publicado: (2021)